- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Piramal Pharma Limited has announced a board meeting and approved the financial results for the quarter and financial year ended March 31, 2025. The company reported standalone total income of Rs. 5,493 Cr and profit after tax of Rs. 691 Cr for the year. A final dividend of Rs. 0.14 per equity share has been proposed, subject to shareholder approval. Leadership changes include the resignation of Non-Executive Director Neeraj Bharadwaj, replaced by Amit Jain from Carlyle, and the re-appointment of Independent Director Jairaj Purandare for a second term. Deloitte Haskins & Sells LLP audited the results with an unmodified opinion.